Clinical Trial: Evaluation of a Rat Sarcoma Oncogene (RAS) Inhibitor in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07252479) titled 'Evaluation of a Rat Sarcoma Oncogene (RAS) Inhibitor in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations' on Nov. 14.

Brief Summary: The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations. It will help identify doses for use in future testing and establish the safety profile of the drug. The main questions it aims to answer are:

Which dose(s) of AN9025 are safe and tolerable for use in evaluating anti-tumor activity in participants with Rat Sarcoma oncogene (RAS) mutated solid tumors? What medical problems do par...